caa a22 4500 445797924 CHVBK 20180317145131.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s10620-011-1750-7 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1750-7 Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2 [Elektronische Daten] [Tatsuo Kanda, Fumio Imazeki, Ryosaku Azemoto, Yutaka Yonemitsu, Shigeru Mikami, Kazuhiko Kita, Motohide Takashi, Masahiko Sunaga, Shuang Wu, Shingo Nakamoto, Akinobu Tawada, Makoto Arai, Keizo Kato, Yu Yoshida, Yoshihiro Koma, Keiichi Fujiwara, Kenichi Fukai, Noriaki Suzuki, Osamu Yokosuka] Background: The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24weeks. Aims: We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment. Methods: Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0. Results: The overall SVR rate was 82.6% (114 of 138): treatment-naïve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively. Conclusions: The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24weeks for some patients infected with HCV genotype 2 may be superior to that for 16weeks. More precise patient selection will be needed to shorten the combination treatment. Springer Science+Business Media, LLC, 2011 Antiviral treatment nationallicence HCV nationallicence Genotype 2 nationallicence Sustained virological response nationallicence Ribavirin nationallicence Kanda Tatsuo Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Imazeki Fumio Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Azemoto Ryosaku Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut Yonemitsu Yutaka Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Mikami Shigeru Kikkoman Hospital, 278-0005, Noda, Japan aut Kita Kazuhiko Chiba Kaihin Municipal Hospital, 261-0012, Chiba, Japan aut Takashi Motohide Saiseikai Narashino Hospital, 275-0006, Narashino, Japan aut Sunaga Masahiko Chiba Central Medical Center, 264-0017, Chiba, Japan aut Wu Shuang Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Nakamoto Shingo Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Tawada Akinobu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Arai Makoto Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Kato Keizo Japanese Red Cross Narita Hospital, 286-8523, Narita, Japan aut Yoshida Yu Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut Koma Yoshihiro Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut Fujiwara Keiichi Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Fukai Kenichi Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Suzuki Noriaki Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut Yokosuka Osamu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/11(2011-11-01), 3335-3342 0163-2116 56:11<3335 2011 56 10620 https://doi.org/10.1007/s10620-011-1750-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1750-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kanda Tatsuo Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Imazeki Fumio Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Azemoto Ryosaku Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut NATIONALLICENCE 700 1- Yonemitsu Yutaka Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Mikami Shigeru Kikkoman Hospital, 278-0005, Noda, Japan aut NATIONALLICENCE 700 1- Kita Kazuhiko Chiba Kaihin Municipal Hospital, 261-0012, Chiba, Japan aut NATIONALLICENCE 700 1- Takashi Motohide Saiseikai Narashino Hospital, 275-0006, Narashino, Japan aut NATIONALLICENCE 700 1- Sunaga Masahiko Chiba Central Medical Center, 264-0017, Chiba, Japan aut NATIONALLICENCE 700 1- Wu Shuang Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Nakamoto Shingo Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Tawada Akinobu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Arai Makoto Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Kato Keizo Japanese Red Cross Narita Hospital, 286-8523, Narita, Japan aut NATIONALLICENCE 700 1- Yoshida Yu Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut NATIONALLICENCE 700 1- Koma Yoshihiro Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut NATIONALLICENCE 700 1- Fujiwara Keiichi Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Fukai Kenichi Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Suzuki Noriaki Kimitsu Chuo Hospital, 292-8535, Kisarazu, Japan aut NATIONALLICENCE 700 1- Yokosuka Osamu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/11(2011-11-01), 3335-3342 0163-2116 56:11<3335 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer